Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy (VIPe-study): A multicenter observational open-label study

Saudi Medical Journal

Volumn 28, Issue 9, 2007, Pages 1402-1407

  Deleu, Dirk ^a   Al Hail, Hassan ^a   Mesraoua, Boulenouar ^a   Mahmoud, Hisham A ^b  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEPAKINE CHRONO; UNCLASSIFIED DRUG; VALPROIC ACID; ANTICONVULSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE DURATION; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; REMISSION; SAUDI ARABIA; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TREMOR; WEIGHT GAIN; CHILD; COHORT ANALYSIS; DELAYED RELEASE FORMULATION; MIDDLE AGED; MIDDLE EAST; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST; TREATMENT OUTCOME; VALPROIC ACID;

EID: 38849172619     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43: 1402-1409.
2. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 61: 433-443.
3. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58 (suppl 5): S2-S8.
4. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-175.
5. Perucca E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
6. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995; 37: 97-108.
7. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50.
8. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomized comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-713.
9. Doughty J, Baker GA, Jacoby A, Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 2003; 4: 710-716.
10. Deleu D, Aarons L, Ahmed IA. Population pharmacokinetics of free-carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol 2001; 57: 243-248.
11. Deleu D, Aarons L, Ahmed IA. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Arch Med Res 2005; 36: 49-53. (Erratum Arch Med Res2005; 36: 186)
12. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.
13. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-399.
14. Hanssens Y, Deleu D, Al Balushi K, Al Hashar A, Al-Zakwani I. Drug utilization pattern of anti-epileptic drugs: A pharmacoepidemiologic study in Oman. J Clin Pharm Ther 2002; 27: 357-364.
15. Hanssens Y, Al-Asmi A, Al-Busaidi I, Deleu D. Efficacy and tolerability of antiepileptic drugs in an Omani epileptic population. Clin Neurol Neurosurg 2006; 108: 532-538.
16. Aziz H, Guvener A, Akhtar SW, Hasan KZ. Comparative epidemiology of epilepsy in Pakistan and Turkey: Population-based studies using identical protocols. Epilepsia 1997; 38: 716-722.
17. Abduljabbar M, Ogunniyi A, Daif AK, Al-Tahan A, Al-Bunyan M, Al-Rajeh S. Epilepsy classification and factors associated with control in Saudi adult patients. Seizure 1998; 7: 501-504.
18. Sander JW. Some aspects of prognosis in the epilepsies: A review. Epilepsia 1993; 34: 1007-1016.
19. Mattson RH, Cramer JA, Collins JF. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Neurology 1996; 47: 68-76.
20. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: A follow-up study of 355 patients with chronic antiepileptic drug treatment. Epilepsia 1988; 29: 787-793.
21. Heaney DC, Shorvon SD, Sander JW, Boon P, Komarek V, Marusic P, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000; 41 Suppl 5: S37-S44.
22. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: Study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247-262.
23. Das CP, Sawhney IM, Lal V, Prabhakar S. Risk of recurrence of seizures following single unprovoked idiopathic seizure. Neurol India 2000; 48: 357-360.